• 1
    Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 168595.
  • 2
    Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002; 252: 28394.
  • 3
    Crea F, Monaco C, Lanza GA et al. Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clin Cardiol 2002; 25: 4616.
  • 4
    Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Engl J Med 2000; 343: 113947.
  • 5
    Mueller C, Laule-Kilian K, Christ A, Brunner-La Rocca HP, Perruchoud AP. Inflammation and long-term mortality in acute congestive heart failure. Am Heart J 2006; 151: 84550.
  • 6
    Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004; 109: 19559.
  • 7
    Biasucci LM, Liuzzo G, Grillo RL et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 85560.
  • 8
    Liuzzo G, Biasucci LM, Gallimore JR et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 41724.
  • 9
    Liuzzo G, Biasucci LM, Rebuzzi AG et al. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation 1996; 94: 237380.
  • 10
    James SK, Armstrong P, Barnathan E et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003; 41: 91624.
  • 11
    Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 2001; 286: 210713.
  • 12
    Suleiman M, Khatib R, Agmon Y et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 2006; 47: 9628.
  • 13
    Ingelsson E, Arnlov J, Sundstrom J, Lind L. Inflammation, as measured by the erythrocyte sedimentation rate, is an independent predictor for the development of heart failure. J Am Coll Cardiol 2005; 45: 18026.
  • 14
    Vasan RS, Sullivan LM, Roubenoff R et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003; 107: 148691.
  • 15
    Hartford M, Wiklund O, Mattsson Hulten L et al. CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int J Cardiol 2006; 108: 5562.
  • 16
    Perers E, Caidahl K, Herlitz J, Karlson BW, Karlsson T, Hartford M. Treatment and short-term outcome in women and men with acute coronary syndromes. Int J Cardiol 2005; 103: 1207.
  • 17
    Perers E, Caidahl K, Herlitz J et al. Spectrum of acute coronary syndromes: history and clinical presentation in relation to sex and age. Cardiology 2004; 102: 6776.
  • 18
    Barton BE. The biological effects of interleukin 6. Med Res Rev 1996; 16: 87109.
  • 19
    Cybulsky MI, Gimbrone Jr MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251: 78891.
  • 20
    Hurt-Camejo E, Camejo G, Peilot H, Oorni K, Kovanen P. Phospholipase A(2) in vascular disease. Circ Res 2001; 89: 298304.
  • 21
    Mueller C, Buettner HJ, Hodgson JM et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002; 105: 14125.
  • 22
    James SK, Oldgren J, Lindback J, Johnston N, Siegbahn A, Wallentin L. An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease. Am Heart J 2005; 149: 61926.
  • 23
    Buffon A, Biasucci LM, Liuzzo G, D’Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347: 512.
  • 24
    Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985; 71: 699708.
  • 25
    Mauriello A, Sangiorgi G, Fratoni S et al. Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction. J Am Coll Cardiol 2005; 45: 158593.
  • 26
    Tanaka A, Shimada K, Sano T et al. Multiple plaque rupture and C-reactive protein in acute myocardial infarction. J Am Coll Cardiol 2005; 45: 15949.
  • 27
    Abbate A, Bonanno E, Mauriello A et al. Widespread myocardial inflammation and infarct-related artery patency. Circulation 2004; 110: 4650.
  • 28
    Cusack MR, Marber MS, Lambiase PD, Bucknall CA, Redwood SR. Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol 2002; 39: 191723.
  • 29
    Lewis EF, Moye LA, Rouleau JL et al. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol 2003; 42: 144653.
  • 30
    Kell R, Haunstetter A, Dengler TJ, Zugck C, Kubler W, Haass M. Do cytokines enable risk stratification to be improved in NYHA functional class III patients? Comparison with other potential predictors of prognosis Eur Heart J 2002; 23: 708.
  • 31
    Von Haehling S, Anker SD. Future prospects of anticytokine therapy in chronic heart failure. Expert Opin Investig Drugs 2005; 14: 16376.
  • 32
    Pearson TA, Bazzarre TL, Daniels SR et al. American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation 2003; 107: 64551.
  • 33
    Mallat Z, Steg PG, Benessiano J et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol 2005; 46: 124957.
  • 34
    Boekholdt SM, Keller TT, Wareham NJ et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 2005; 25: 83946.
  • 35
    Anker SD, Von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004; 90: 46470.
  • 36
    Nissen SE, Tuzcu EM, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 2938.
  • 37
    Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 208.
  • 38
    Wiklund O, Mattsson-Hulten L, Hurt-Camejo E, Oscarsson J. Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med 2002; 251: 33847.
  • 39
    De Servi S, Mariani M, Mariani G, Mazzone A. C-reactive protein increase in unstable coronary disease cause or effect? J Am Coll Cardiol 2005; 46: 1496502.